Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma

被引:23
作者
Mu, XC
Tran, TA
Ross, JS
Carlson, JA
机构
[1] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA
[2] Samuel S Stratton Vet Adm Med Ctr, Div Dermatopathol & Dermatol, Albany, NY USA
[3] Samuel S Stratton Vet Adm Med Ctr, Dept Pathol & Lab Med, Albany, NY USA
关键词
D O I
10.1034/j.1600-0560.2000.027005242.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Malignant melanoma (MM) is considered to be a chemotherapy-refractory tumor. New anti-cancer drugs (e.g. etoposide) that target DNA topoisomerases (e.g. topoisomerase II-alpha (topo II alpha)) show activity against a wide variety of solid tumors. In this study, we investigated the frequency and rate of labeling for topo II alpha in 163 MMs (primary and metastatic) and 67 melanocytic nevi to determine whether topo II alpha expression is elevated in MM. Primary MM exhibited significantly more frequent topo II alpha expression compared to benign nevi (86% vs. 56%, p=0.0001). The rate of topo II alpha labeling in dysplastic melanocytic nevi, radial growth phase MM, vertical growth phase MM and metastatic MM revealed significant differences amongst groups and a positive covariance with advancing stage (means: 0.3, 0.5, 5, and 8 '+' cells/hpf, respectively; r=0.3, all p less than or equal to 0.02). Topo II alpha labeling significantly correlated with increasing mitotic activity, depth of invasion and Clark's level, diminishing tumor infiltrating lymphocytes, and poor outcome (all p less than or equal to 0.01) in primary MM. For metastatic MM, a minority (30%) exhibited marked elevation of topo II alpha expression. These findings indicate topo II alpha as a potential therapeutic target and marker for MM. Immunohistochemical analysis of disseminated MM may allow for correlation with clinical response and enable selection of candidates sensitive for specific chemotherapy.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 46 条
[1]  
Brown MS, 1998, AM J CLIN PATHOL, V109, P39
[2]   Acquisition of multiple copies of a mutant topoisomerase II alpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines [J].
Campain, JA ;
Slovak, ML ;
Schoenlein, PV ;
Popescu, NC ;
Gottesman, MM ;
Pastan, I .
SOMATIC CELL AND MOLECULAR GENETICS, 1995, 21 (06) :451-471
[3]   A NOVEL MUTANT TOPOISOMERASE II-ALPHA PRESENT IN VP-16-RESISTANT HUMAN-MELANOMA CELL-LINES HAS A DELETION OF ALANINE-429 [J].
CAMPAIN, JA ;
GOTTESMAN, MM ;
PASTAN, I .
BIOCHEMISTRY, 1994, 33 (37) :11327-11332
[4]  
Clark W H Jr, 1975, Semin Oncol, V2, P83
[5]   MODEL PREDICTING SURVIVAL IN STAGE-I MELANOMA BASED ON TUMOR PROGRESSION [J].
CLARK, WH ;
ELDER, DE ;
GUERRY, D ;
BRAITMAN, LE ;
TROCK, BJ ;
SCHULTZ, D ;
SYNNESTVEDT, M ;
HALPERN, AC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) :1893-1904
[6]   Current treatment options for malignant melanoma [J].
Cohen, GL ;
Falkson, CI .
DRUGS, 1998, 55 (06) :791-799
[7]  
Cole S P, 1996, Cancer Treat Res, V87, P39
[8]  
DAVIES SM, 1988, J BIOL CHEM, V263, P17724
[9]  
Guinee DG, 1996, CANCER, V78, P729
[10]   Systemic therapy of malignant melanoma [J].
Hansson, J .
MEDICAL ONCOLOGY, 1997, 14 (02) :73-81